#BMRA

Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand Biomerica (Nasdaq: BMRA) announced an expansion of its Contract Development and Manufacturing Organization (CDMO) services on Nov 6, 2025 to meet rising demand from diagnostic and biotechnology companies.The company highlighted end-to-end capabilities across LFA, point-of-care, ELISA, multiplex ELISA, antibody/reagent services, recombinant antibody development, manufacturing/assembly, and global supply chain & technology transfer. Biomerica cited ISO 13485, CE-mark expertise, and an FDA-registered cGMP facility and said CDMO work is a growing contributor to revenue.

4 months ago

#BMRA Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand

www.stocktitan.net/news/BMRA/biomerica-expa...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Oct 16th - #WHWK #WATT #SOND #REE #PRAX #KCHV #DTIL #CBIO #BMRA #ANY - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S. Biomerica (NASDAQ: BMRA) announced on October 16, 2025 a marketing services agreement with Henry Schein (NASDAQ: HSIC) to market the inFoods® Irritable Bowel Syndrome (IBS) test across the U.S., excluding New York State. Henry Schein will leverage its nationwide network of >400 medical field sales and telesales representatives to promote the non‑drug, precision diagnostic therapy to primary care and gastroenterology practices.A multicenter, double‑blinded study published in Gastroenterology (June 2025) showed statistically significant outcomes: 59.6% treatment vs 42.2% control for abdominal pain reduction overall; 67.1% vs 35.8% in IBS‑C; 66% vs 29.5% in IBS‑M. IBS affects an estimated 10–15% of U.S. adults.

5 months ago

#BMRA Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.

www.stocktitan.net/news/BMRA/henry-schein-a...

0 0 0 0

Biomerica Reports First Quarter Fiscal 2026 Financial Results Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational Efficiency Earnings per Share $0.00, Compared to a

5 months ago

#BMRA Biomerica Reports First Quarter Fiscal 2026 Financial Results

www.stocktitan.net/news/BMRA/biomerica-repo...

0 0 0 0

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes Biomerica (Nasdaq: BMRA) has launched the inFoods® IBS Trigger Food Navigator, an AI-powered digital tool designed to enhance their existing IBS diagnostic solution. The Navigator helps patients better manage their IBS symptoms by providing smart meal suggestions and ingredient substitutions based on their personalized trigger food profile.The company's clinical studies showed significant results, with 59.6% of treatment group patients achieving FDA's endpoint for abdominal pain reduction compared to 42.2% in the control group. Even higher success rates were observed in IBS-C (67.1%) and IBS-M (66.0%) patients.Developed with University of Michigan dietitians, the Navigator includes features like smart food identification, AI-driven meal suggestions, and an alternative food database. The tool is provided at no additional cost to existing inFoods® IBS test customers and is available through healthcare providers or online for new patients.

6 months ago

#BMRA Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

www.stocktitan.net/news/BMRA/biomerica-laun...

0 0 0 0

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use Biomerica (NASDAQ:BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Kidney Test for home use. The 10-minute diagnostic test detects early kidney damage by identifying low albumin levels in urine, particularly targeting patients with diabetes and hypertension.The approval addresses a significant market, as approximately 25% of UAE nationals have diabetes, while hypertension affects 31% of adults in the region. The test will be distributed through pharmacies, clinics, and hospitals throughout the UAE, expanding Biomerica's presence in the Middle East following the success of its EZ Detect™ Colon Disease Test.

6 months ago

#BMRA United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

www.stocktitan.net/news/BMRA/united-arab-em...

0 0 0 0

Biomerica Reports Fiscal 2025 Year End Results Biomerica (NASDAQ: BMRA) reported its fiscal year 2025 results, showing a 19% improvement in operating loss to $5.1 million despite slight revenue decline. The company achieved $5.3 million in revenue, down from $5.4 million in the previous year, with gross profit at $498,000.Key achievements include $1.3 million in operating expense reductions and improved cash management, with cash used in operations decreasing to $3.8 million from $5.3 million. Strategic milestones include receiving a PLA code for inFoods® IBS test, expanding in the MENA region, and launching direct-to-consumer availability of inFoods® IBS with a new patient self-collection system.The company secured EU IVDR certification for food-intolerance diagnostic tests and obtained three new international patents for its inFoods® technology platform applications in various gastrointestinal conditions.

6 months ago

#BMRA Biomerica Reports Fiscal 2025 Year End Results

www.stocktitan.net/news/BMRA/biomerica-repo...

0 0 0 0

6 months ago

🚀 Exciting times for #BMRA! With increased volatility and a price above its 10-day SMA, short-term bullish momentum is in play. Consider a long position at $3.20, targeting $3.40 & $3.50. Stay alert for market shifts! 📈 #StockMarket #FeetrAI

0 0 0 0

6 months ago

🚀 Exciting times for #BMRA! With trading volumes below average, volatility is on the horizon. Current price near 10-day SMA suggests support. Consider a long position at $3.15, targeting $3.30 & $3.40. Stay alert for volume spikes! 📈 #StockWatch #FeetrAI

0 0 0 0

6 months ago

🚨 FeetrAI Alert: #BMRA is in the spotlight! Trading at $3.06 with low liquidity, it's showing bearish signals. RSI suggests oversold, MACD points down. Consider a SHORT at $3.05, targeting $2.90 & $2.80. Stop loss at $3.15. Caution advised—volatility ahead! 📉 #Stocks #Trading

0 0 0 0

6 months ago

🚨 FeetrAI Alert: #BMRA is in consolidation mode at $3.01 with bearish signals! 📉 RSI < 50 & negative MACD hint at more downside. Volume's low, so watch for volatility. Consider SHORT at $3.00, target $2.85/$2.70, stop loss $3.15. Trade smart! 💡 #StockMarket #TradingTips

0 0 0 0

6 months ago

🚨 FeetrAI Alert: #BMRA is trading at $3 with a neutral to bearish outlook. Resistance looms at $3.15 & $3.26, while RSI at 47 shows no extremes. Weak momentum & cautious market sentiment suggest a short position. Target: $2.90/$2.75, Stop: $3.20. Stay sharp! 📉 #Stocks #Trading

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #BMRA is in the spotlight! Trading at $3, with mixed signals: 10-day SMA below 20 & 30-day, RSI at 47, and negative MACD. High volume hints at speculation. Consider shorting at $3.05, targeting $2.85 & $2.70, stop loss at $3.20. Stay sharp! 📉📈 #Stocks #Trading

0 0 0 0

7 months ago

🚀 Exciting times for #BMRA! Trading volume is soaring after a new non-invasive diagnostic test announcement. With bullish momentum above key moving averages, consider a long position at $3.80. Target: $4.20 & $4.50. Stop loss: $3.50. Stay tuned for more updates! 📈 #FeetrAI

0 0 0 0

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use Biomerica (Nasdaq: BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test for home use. This 10-minute diagnostic test detects antibodies to Helicobacter pylori (H. pylori), a bacterium affecting 41% of the UAE population and linked to approximately 80% of gastric cancer cases.The test will be distributed through UAE-based partners and made available at pharmacies, clinics, and online platforms. H. pylori, classified as a Class 1 carcinogen by WHO, can lead to serious complications in up to 20% of infected individuals if untreated, including peptic ulcers and gastric cancer. This approval strengthens Biomerica's presence in the Middle East market, following their successful launch of the EZ Detect™ Colon Disease Test.

7 months ago

#BMRA United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use

www.stocktitan.net/news/BMRA/united-arab-em...

0 0 0 0

Diagnostics Leader Who Drove $100M Revenue Growth Joins Biomerica to Scale IBS Testing Innovation Former Boston Heart Diagnostics President to accelerate inFoods IBS commercialization and payer strategy. See how his track record could transform BMRA's market presence.

8 months ago

#BMRA Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer

www.stocktitan.net/news/BMRA/clinical-diagn...

0 0 0 0

Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology Biomerica announced the publication of its pivotal clinical trial results for the inFoods® IBS test in Gastroenterology journal. The randomized, multicenter, double-blind study involving 238 patients across eight U.S. academic centers demonstrated significant symptom improvement in IBS patients following a personalized elimination diet. The treatment group showed 59.6% of patients achieving FDA-defined abdominal pain reduction versus 42.2% in the control group. Notably, IBS-M patients showed remarkable improvement with 66% meeting treatment targets compared to 29.5% in controls. The test, which identifies specific foods triggering immune responses in IBS patients, showed particular promise for IBS-M patients, who represent 33% of the IBS market and currently lack FDA-approved drug treatments.

9 months ago

#BMRA Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology

www.stocktitan.net/news/BMRA/biomerica-s-in...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

#BMRA inFoods IBS achieves ~49% reduction in IBS symptoms like pain & bloating in real-world data! Personalized diet
#biomerica #inFoodsIBS #IBS
prismmarketview.com/biomericas-i...

0 0 0 0

Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System Biomerica (NASDAQ: BMRA) reported significant real-world data for its inFoods® IBS diagnostic-guided therapy, showing remarkable symptom reduction in IBS patients. Data from over 360 patients demonstrated a 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period.The company also launched a HIPAA-compliant real-time patient feedback system that enables physicians to track symptoms and adjust treatment plans accordingly. These results complement a peer-reviewed study published in Gastroenterology, which showed that patients on an inFoods® IBS-guided diet experienced significantly more abdominal pain relief compared to placebo (59.6% vs. 42.1%, p-value=0.02).The solution targets a substantial market, as IBS affects 10-15% of U.S. adults, offering a personalized, non-drug approach to identify and eliminate specific food triggers causing IBS symptoms.

9 months ago

#BMRA Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

www.stocktitan.net/news/BMRA/biomerica-repo...

0 0 0 0

PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement Biomerica (NASDAQ: BMRA) has submitted a Proprietary Laboratory Analysis (PLA) code application to the American Medical Association for its inFoods® IBS diagnostic test. This represents a crucial step toward obtaining insurance reimbursement and expanding patient access. The inFoods® IBS test is a non-invasive diagnostic tool that identifies patient-specific foods triggering IBS symptoms like bloating, abdominal pain, diarrhea, and constipation. A published clinical trial in Gastroenterology demonstrated significantly greater symptom relief in patients following personalized diets based on test results compared to placebo. The test addresses a significant market, as IBS affects 10-15% of U.S. adults and contributes to billions in healthcare costs annually. The test is currently available for direct-to-consumer ordering through www.inFoodsIBS.com.

10 months ago

#BMRA PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

www.stocktitan.net/news/BMRA/pla-code-appli...

0 0 0 0

Biomerica Secures Major UAE Approval for Rapid H. Pylori Test as Middle East Expansion Accelerates New rapid diagnostic targets 50% infection rate in UAE market. Detects WHO Class 1 carcinogen linked to 80% of gastric cancers. See market potential.

10 months ago

#BMRA United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection

www.stocktitan.net/news/BMRA/united-arab-em...

0 0 0 0

Market Wire News

@marketwirenews.com

10 months ago

News; ( NASDAQ: #BMRA ) BMRA announced stock split 1-8

0 0 0 0